Iovance Biotherapeutics (IOVA) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free IOVA Stock Alerts $10.97 -2.48 (-18.44%) (As of 05/10/2024 08:55 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down to $13.45americanbankingnews.com - May 12 at 4:03 AMThe 3 Most Undervalued Biotech Stocks to Buy in May 2024investorplace.com - May 11 at 10:00 AMIovance Biotherapeutics Poised for Growth: Analyst Reiterates Buy Rating Amid Strong Q1 Performance and Promising Clinical Advancementsmarkets.businessinsider.com - May 11 at 6:49 AMIovance Biotherapeutics Reports a Q1 Revenue Missfool.com - May 11 at 6:49 AMIovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...finance.yahoo.com - May 11 at 6:49 AMIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcriptmsn.com - May 11 at 6:49 AMIovance Biotherapeutics (NASDAQ:IOVA) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPSmarketbeat.com - May 10 at 11:46 PMIovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from HC Wainwrightmarketbeat.com - May 10 at 6:18 PMIovance Biotherapeutics's Options: A Look at What the Big Money is Thinkingbenzinga.com - May 10 at 3:45 PMIovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagviseekingalpha.com - May 10 at 2:40 PMWhy Iovance Stock Is Down 18% Todayfool.com - May 10 at 2:03 PMIovance Biotherapeutics: A Strong Buy on Robust Growth Potential and Early Launch Successmarkets.businessinsider.com - May 10 at 6:29 AMIOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024investorplace.com - May 9 at 10:06 PMIovance Biotherapeutics: Q1 Earnings Snapshotsfgate.com - May 9 at 8:28 PMIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updatesfinance.yahoo.com - May 9 at 8:28 PMIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updatesglobenewswire.com - May 9 at 4:01 PMIovance Biotherapeutics (IOVA) Set to Announce Quarterly Earnings on Thursdayamericanbankingnews.com - May 8 at 4:57 AMInvestors Purchase Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)americanbankingnews.com - May 7 at 1:32 AMInvestors Buy High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)marketbeat.com - May 6 at 2:03 PMGot $500? These Hot Growth Stocks Are Screaming Buys Right Nowfool.com - May 5 at 7:01 PMIovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Thursdaymarketbeat.com - May 2 at 10:17 AMFirst FDA-approved cellular therapy for metastatic melanoma available in South Floridamsn.com - May 2 at 2:28 AMIovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024globenewswire.com - May 1 at 6:01 AMAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)markets.businessinsider.com - May 1 at 4:12 AMIovance Biotherapeutics to Present at Upcoming Conferencesglobenewswire.com - April 30 at 6:01 AMWhere Will Iovance Biotherapeutics Stock Be in 5 Years?fool.com - April 28 at 2:44 PMParametrica Management Ltd Acquires 224,876 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - April 28 at 12:17 PMThe Top 3 Biotech Stocks to Buy in April 2024investorplace.com - April 27 at 7:00 AMIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Buy" by Brokeragesmarketbeat.com - April 27 at 4:28 AMIovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meetingglobenewswire.com - April 24 at 4:01 PMThese Biotech Stocks Could Soar 120% and 295%, According to Wall Streetfool.com - April 21 at 5:08 AMIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - April 19 at 5:15 PMIovance Biotherapeutics, Inc. Expected to Earn FY2024 Earnings of ($1.57) Per Share (NASDAQ:IOVA)marketbeat.com - April 17 at 5:39 PMIs Iovance Biotherapeutics Stock a Buy Now?fool.com - April 17 at 9:45 AMIovance Biotherapeutics Enters Oversold Territory (IOVA)nasdaq.com - April 17 at 2:32 AMFirst Week of May 31st Options Trading For Iovance Biotherapeutics (IOVA)nasdaq.com - April 17 at 2:32 AMMarket Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)finance.yahoo.com - April 17 at 2:32 AMThe Top 5 Analysts Ranked by Marketbeat and Stocks They Covermarketbeat.com - April 9 at 7:01 AMThe Top 5 Analysts Ranked by Marketbeat and Stocks They Cover (IOVA)marketbeat.com - April 9 at 7:00 AMIovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Resultsseekingalpha.com - April 9 at 6:05 AMIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 3.7% marketbeat.com - April 8 at 2:30 PMBetter Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeuticsfool.com - April 5 at 5:03 AMVanguard Group Inc. Purchases 1,748,082 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - April 5 at 4:07 AMObsidian lands $160M Series C —but IPO still in the cardsbizjournals.com - April 3 at 5:05 PMBuy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in Immunotherapymarkets.businessinsider.com - April 3 at 7:03 AMSG Americas Securities LLC Sells 187,664 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)marketbeat.com - April 3 at 4:18 AMAnalysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)markets.businessinsider.com - April 1 at 2:43 AMCity Council wants the gene therapy industry to hire Philadelphians without a college degreemsn.com - March 29 at 12:47 PMIovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?finance.yahoo.com - March 29 at 12:47 PMIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 6%marketbeat.com - March 28 at 8:23 PM Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him IOVA Media Mentions By Week IOVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.580.58▲Average Medical News Sentiment IOVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼236▲IOVA Articles Average Week Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Immunovant News Today SpringWorks Therapeutics News Today Krystal Biotech News Today CRISPR Therapeutics News Today Immunocore News Today Arcellx News Today Halozyme Therapeutics News Today Twist Bioscience News Today Denali Therapeutics News Today Vericel News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityElon’s New Device is About to Shock the WorldInvestorPlaceThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon to Transform U.S. Economy? Porter & CompanyBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
